Feb 9 (Reuters) - Privately held Iambic said on Monday it has entered a multi-year partnership worth more than $1.7 billion with Japan's Takeda Pharmaceutical to use artificial intelligence to help design small-molecule drugs targeting cancer and gastrointestinal diseases.
Under the agreement, Iambic will receive upfront payments and could earn more than $1.7 billion in development and commercial milestones, plus royalties on sales.
